We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Former FDA Commissioner Scott Gottlieb strongly defended the agency’s approach to getting a vaccine out to the public in the shortest amount of time, criticizing the Trump administration’s apparent attempt to derail a planned guidance the president believes could reduce the chance of having a proven vaccine before the November election. Read More
Two leading COVID-19 vaccine developers, AstraZeneca and Moderna, have hit new speed bumps that could delay their promising COVID-19 vaccine candidates, reducing the possibility of a vaccine being ready ahead of the U.S. presidential election on Nov. 3. Read More
Individuals over the age of 65 are likely to be excluded from more than 50 percent of trials studying COVID-19 therapies and 100 percent of COVID-19 vaccine trials, despite the fact that these older patients account for more than 80 percent of deaths related to the disease, according to a new study in JAMA Internal Medicine. Read More
The National Institute of Allergy and Infectious Diseases (NIAID) has stopped enrolling severely ill COVID-19 patients in a phase 3 trial of Merck’s Rebif (interferon beta-1a) with Gilead Sciences’ remdesivir because of serious adverse events. Read More
The University of Oxford is gearing up to launch a trial of the anti-inflammatory drug adalimumab as a treatment for COVID-19 patients in community care homes. Read More